A Bcr-Abl Inhibitor GNF-2 Attenuates Inflammatory Activation of Glia and Chronic Pain

Area of Science:

• Neuroscience
• Pharmacology
• Immunology

Background:

• c-Abl tyrosine kinase is implicated in neuroprotection.
• The role of c-Abl and GNF-2 in glia-mediated neuroinflammation and pain is unexplored.
• GNF-2 is an allosteric inhibitor of Bcr-Abl, developed for resistant chronic myelogenous leukemia.

Purpose of the Study:

• To investigate the role of c-Abl in glia-mediated neuroinflammation and pain.
• To determine the effects of GNF-2 on glial activation and pain behaviors.
• To test if c-Abl inhibition by GNF-2 can attenuate inflammatory activation of glia and pain.

Main Methods:

• In vitro studies using cultured glial cells treated with lipopolysaccharide (LPS).
• Assessed nitric oxide and pro-inflammatory cytokine production.
• Utilized small interfering ribonucleic acid (siRNA) for c-Abl knockdown.
• Evaluated GNF-2 administration in animal models of diabetic and inflammatory pain.

Main Results:

• GNF-2 reduced LPS-induced nitric oxide and pro-inflammatory cytokine production in glial cells, dependent on c-Abl.
• siRNA-mediated knockdown of c-Abl attenuated LPS-induced nuclear factor kappa light chain enhancer of activated B cell (NF-κB) activation and pro-inflammatory mediator production.
• GNF-2 administration significantly reduced mechanical and thermal hypersensitivities in pain models.

Conclusions:

• c-Abl is involved in neuroinflammation and pain pathogenesis.
• GNF-2 attenuates glial inflammatory activation and associated pain behaviors.
• GNF-2 presents a potential therapeutic strategy for managing chronic pain.